Malignant pleural mesothelioma is a rare and fast acting tumor where no effective therapy is around in spite of the breakthrough of several possible molecular and genetic targets. The late stage of MPM diagnosis and the period of time that exists connects some exposures and diagnosis have made it tricky to completely study the importance of risk factors and the resulting molecular effects.
Many health centres are now seeing more patients that have asbestos cancer. Because of this, pathologists studying the case are given a number of problems, that are divided into those encountered in finding the differences between mesothelioma and harmless changes and those seen in differentiating malignant mesotheliomas from different sorts of e-cadherin and tissue tumors that connect. Immunohistochemistry is a major factor in diagnosis, however, it should be understood in regards to the experimental setting and radiological characteristics, and with an understanding of the broad morphological variations existing in mesothelioma.
Cancer of the mesothelium is a cancer directly affecting the serosal cavities, an anatomic location that is also frequently affected by metastasis, predominantly from primary carcinomas of the lung, breast, and ovary. Progression in IHC have lead to improvement in diagnostic sensitivity and mesothelioma in both cytological and histological material. Lately, the authors group applied a high level of throughput technology to the recognition of new flags that may aid in being able to tell the difference between mesothelioma from ovarian and peritoneal cancer, closely related histogenesis found in tumors and antigenic profile. Together with the improved tools obtainable for cancer of the serosa diagnosis, realizing the biology of cancer of the mesothelium has accumulate as of late.
